1. Home
  2. JNJ
  3. JNJ News

Latest Johnson & Johnson (JNJ) News on November 24, 2024

Hedge Funds Bet Big On Johnson & Johnson (JNJ): Top Healthcare Stock to Watch
JNJ

Insider Monkey

a day ago

Hedge Funds Bet Big On Johnson & Johnson (JNJ): Top Healthcare Stock to Watch

3 Dividend Stocks That Are Screaming Buys in November
JNJ

Motley Fool

a day ago

3 Dividend Stocks That Are Screaming Buys in November

2 Unstoppable Dividend Stocks to Buy Now With $500
JNJ

Motley Fool

a day ago

2 Unstoppable Dividend Stocks to Buy Now With $500

2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade
JNJ

Motley Fool

a day ago

2 Dow Jones Dividend Stocks With Yields Above 3% You Can Buy Now and Hold at Least a Decade

Layoffs in 2024: A List of Companies Cutting Jobs This Year
JNJ

The Wall Street Journal

2 days ago

Layoffs in 2024: A List of Companies Cutting Jobs This Year

J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis
JNJ

Pharmaceutical Technology

2 days ago

J&J eyes FDA approval for injection-based Tremfya in ulcerative colitis

Medtronic acquires Fortimedix Surgical to boost surgical portfolio
JNJ

Medical Device Network

2 days ago

Medtronic acquires Fortimedix Surgical to boost surgical portfolio

Sanofi Plans to Change Hospital Drug-Discount Program
JNJ

The Wall Street Journal

2 days ago

Sanofi Plans to Change Hospital Drug-Discount Program

Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma
JNJ

Pharmaceutical Technology

2 days ago

Health Canada issues NOC to J&J’s CARVYKTI for multiple myeloma

JNJ

MT Newswires

2 days ago

Johnson & Johnson Applies for FDA Approval of Tremfya Subcutaneous Induction Regimen for Ulcerative Colitis

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor
JNJ

PR Newswire

2 days ago

Johnson & Johnson seeks U.S. FDA approval for subcutaneous induction regimen of TREMFYA® (guselkumab) in ulcerative colitis, a first for an IL-23 inhibitor

Johnson & Johnson (NYSE:JNJ) Stock Goes Ex-Dividend In Just Three Days
JNJ

Simply Wall St.

2 days ago

Johnson & Johnson (NYSE:JNJ) Stock Goes Ex-Dividend In Just Three Days

Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy
JNJ

CNW Group

3 days ago

Health Canada Authorizes CARVYKTI® (ciltacabtagene autoleucel) for Patients with Relapsed or Refractory Multiple Myeloma Who Have Received One to Three Prior Lines of Therapy

JNJ

MT Newswires

4 days ago

Update: Market Chatter: Johnson & Johnson, Merck Cut Jobs in China

JNJ

MT Newswires

4 days ago

Sector Update: Health Care Stocks Advance Wednesday Afternoon

JNJ

MT Newswires

4 days ago

Market Chatter: Johnson & Johnson, Merck Cut Jobs in China

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting
JNJ

PR Newswire

5 days ago

Johnson & Johnson to showcase strength of its broad hematology portfolio and pipeline at the 2024 American Society of Hematology Annual Meeting

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know
JNJ

Zacks

5 days ago

Johnson & Johnson (JNJ) is Attracting Investor Attention: Here is What You Should Know

J&J pill clears skin in two late-stage psoriasis studies
JNJ

BioPharma Dive

5 days ago

J&J pill clears skin in two late-stage psoriasis studies

Johnson & Johnson reports topline outcomes from trial of icotrokinra for psoriasis
JNJ

Clinical Trials Arena

5 days ago

Johnson & Johnson reports topline outcomes from trial of icotrokinra for psoriasis

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results
JNJ

PR Newswire

6 days ago

Icotrokinra delivered an industry-leading combination of significant skin clearance with demonstrated tolerability in a once daily pill in Phase 3 topline results

How Robert F. Kennedy Jr. could impact the healthcare sector as secretary of health
JNJ

Yahoo Finance

6 days ago

How Robert F. Kennedy Jr. could impact the healthcare sector as secretary of health

Johnson & Johnson appoints CIO to lead business technology strategy
JNJ

CIO Dive

6 days ago

Johnson & Johnson appoints CIO to lead business technology strategy

CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC
JNJ

Zacks

6 days ago

CHMP Endorses J&J's Rybrevant-Lazcluze Combo for Use in NSCLC

Eli Lilly follows J&J in suing Biden administration over 340B rebates
JNJ

Healthcare Dive

6 days ago

Eli Lilly follows J&J in suing Biden administration over 340B rebates

JNJ

Morningstar Research

7 days ago

Analyst Report: Johnson & Johnson

Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program
JNJ

Investopedia

9 days ago

Eli Lilly, J&J Sue US Over Rejected Changes To Drug Discounting Program

Johnson & Johnson MedTech announces partnership for soft tissue solutions
JNJ

Medical Device Network

9 days ago

Johnson & Johnson MedTech announces partnership for soft tissue solutions

J&J’s nipocalimab shows promise in Phase II Sjögren’s disease trial
JNJ

Clinical Trials Arena

9 days ago

J&J’s nipocalimab shows promise in Phase II Sjögren’s disease trial

JNJ

MT Newswires

9 days ago

Wolfe Research Initiates Johnson & Johnson at Outperform With $190 Price Target

Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?
JNJ

Zacks

10 days ago

Why Is Johnson & Johnson (JNJ) Down 6.7% Since Last Earnings Report?

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study
JNJ

PR Newswire

10 days ago

Nipocalimab demonstrates significant clinical improvement in disease activity and IgG reduction in Phase 2 Sjögren's disease study

JNJ

MT Newswires

11 days ago

Sector Update: Health Care Stocks Softer Late Afternoon

JNJ

MT Newswires

11 days ago

Sector Update: Health Care Stocks Edge Lower Wednesday Afternoon

JNJ

MT Newswires

11 days ago

Sector Update: Health Care

Why Johnson & Johnson, Invitation Homes And Extra Space Storage Are Winners For Passive Income
JNJ

Benzinga

11 days ago

Why Johnson & Johnson, Invitation Homes And Extra Space Storage Are Winners For Passive Income

J&J MedTech wins IDE for Ottava to greenlight trials for surgical robot
JNJ

Medical Device Network

11 days ago

J&J MedTech wins IDE for Ottava to greenlight trials for surgical robot

JNJ

MT Newswires

11 days ago

Johnson & Johnson Sues US Government Over Rebate Model in Drug Discount Program

J&J sues federal government for halting 340B rebate plan
JNJ

Healthcare Dive

11 days ago

J&J sues federal government for halting 340B rebate plan

JNJ

Thomson Reuters StreetEvents

11 days ago

Q3 2024 Legend Biotech Corp Earnings Call

TRex Bio raises $84M to compete in crowded immune drug field
JNJ

BioPharma Dive

11 days ago

TRex Bio raises $84M to compete in crowded immune drug field

J&J Sues U.S. Over Hospital Drug-Discounting Program
JNJ

The Wall Street Journal

12 days ago

J&J Sues U.S. Over Hospital Drug-Discounting Program

J&J’s Ottava surgical robot to begin clinical trial after FDA nod
JNJ

MedTech Dive

12 days ago

J&J’s Ottava surgical robot to begin clinical trial after FDA nod

The Art of Valuation: Discovering Johnson & Johnson's Intrinsic Value
JNJ

GuruFocus.com

12 days ago

The Art of Valuation: Discovering Johnson & Johnson's Intrinsic Value

JNJ

MT Newswires

13 days ago

Johnson & Johnson Reports Breakthrough Therapy Designation for Sjogren's Disease Treatment

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease
JNJ

PR Newswire

13 days ago

Nipocalimab is the first and only investigational therapy granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease

Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?
JNJ

Simply Wall St.

13 days ago

Johnson & Johnson's (NYSE:JNJ) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Spravato is just the beginning in a new wave of depression meds
JNJ

Pharma Voice

13 days ago

Spravato is just the beginning in a new wave of depression meds

Why Johnson & Johnson (JNJ)’s Legal Issues Could Wrap Up Quickly
JNJ

Insider Monkey

16 days ago

Why Johnson & Johnson (JNJ)’s Legal Issues Could Wrap Up Quickly

JNJ

Morningstar Research

16 days ago

Analyst Report: Johnson & Johnson

JNJ

MT Newswires

16 days ago

Johnson & Johnson Applies for US, EU Approval of Darzalex to Treat Smoldering Multiple Myeloma

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma
JNJ

PR Newswire

16 days ago

Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO® / DARZALEX® as subcutaneous monotherapy for high-risk smoldering multiple myeloma

Johnson & Johnson MedTech’s VARIPULSE Platform receives FDA approval for AFib
JNJ

Medical Device Network

16 days ago

Johnson & Johnson MedTech’s VARIPULSE Platform receives FDA approval for AFib

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever
JNJ

Motley Fool

16 days ago

Want Decades of Passive Income? 2 Stocks to Buy Now and Hold Forever

FDA Greenlights J&J's Varipulse Device for Safer Atrial Fibrillation Treatment
JNJ

GuruFocus.com

17 days ago

FDA Greenlights J&J's Varipulse Device for Safer Atrial Fibrillation Treatment

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024
JNJ

PR Newswire

17 days ago

Johnson & Johnson advances leadership in rheumatic disease innovation with 43 abstracts at ACR 2024

J&J wins FDA approval for Varipulse PFA system
JNJ

MedTech Dive

17 days ago

J&J wins FDA approval for Varipulse PFA system

JNJ

MT Newswires

18 days ago

Guggenheim Adjusts Johnson & Johnson's Price Target to $162 From $156, Keeps Neutral Rating

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It
JNJ

Zacks

19 days ago

Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It

With 73% ownership of the shares, Johnson & Johnson (NYSE:JNJ) is heavily dominated by institutional owners
JNJ

Simply Wall St.

19 days ago

With 73% ownership of the shares, Johnson & Johnson (NYSE:JNJ) is heavily dominated by institutional owners

Is Johnson & Johnson (JNJ) the Best Pharma Stock to Buy Right Now?
JNJ

Insider Monkey

20 days ago

Is Johnson & Johnson (JNJ) the Best Pharma Stock to Buy Right Now?

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare
JNJ

GlobeNewswire

20 days ago

Empower 2024 Delivers Groundbreaking Insights and Innovation to Achieve Data-Driven Healthcare

JNJ

Argus Research

20 days ago

Weekly Stock List

Johnson & Johnson MedTech concludes enrolment for OMNY-AF trial pilot phase
JNJ

Medical Device Network

23 days ago

Johnson & Johnson MedTech concludes enrolment for OMNY-AF trial pilot phase

J&J Medtech CIO Larry Jones resigns
JNJ

MedTech Dive

23 days ago

J&J Medtech CIO Larry Jones resigns

The Zacks Analyst Blog Highlights Amazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction
JNJ

Zacks

24 days ago

The Zacks Analyst Blog Highlights Amazon.com, Johnson & Johnson, Boston Scientific and Armanino Foods of Distinction

Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions
JNJ

Pharmaceutical Technology

24 days ago

Psoriasis biosimilars and pricing changes herald treatment paradigm disruptions

Top Stock Reports for Amazon.com, Johnson & Johnson and Boston Scientific
JNJ

Zacks

25 days ago

Top Stock Reports for Amazon.com, Johnson & Johnson and Boston Scientific

JNJ

MT Newswires

a month ago

Grifols's Fibrin Sealant Approved by FDA for Children; Shares Rise

J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s disease
JNJ

Clinical Trials Arena

a month ago

J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s disease

Invest with Confidence: Intrinsic Value Unveiled of Johnson & Johnson
JNJ

GuruFocus.com

a month ago

Invest with Confidence: Intrinsic Value Unveiled of Johnson & Johnson

J&J to seek FDA approval after small-bore Impella heart pump hits trial goal
JNJ

MedTech Dive

a month ago

J&J to seek FDA approval after small-bore Impella heart pump hits trial goal

J&J’s $8.2 Billion Talc Settlement Faces January Court Test
JNJ

Bloomberg

a month ago

J&J’s $8.2 Billion Talc Settlement Faces January Court Test

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion
JNJ

The Wall Street Journal

a month ago

AbbVie to Acquire Aliada Therapeutics for $1.4 Billion

Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
JNJ

Benzinga

a month ago

Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease

JNJ

MT Newswires

a month ago

Johnson & Johnson Says Phase 3 Trial of Crohn's Disease Treatment Showed High Remission Rates

This Johnson & Johnson Insider Reduced Their Stake By 37%
JNJ

Simply Wall St.

a month ago

This Johnson & Johnson Insider Reduced Their Stake By 37%

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease
JNJ

PR Newswire

a month ago

TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to demonstrate robust results with a fully subcutaneous regimen in both induction and maintenance in Crohn's disease

3 Dividend Stocks to Double Up on Right Now
JNJ

Motley Fool

a month ago

3 Dividend Stocks to Double Up on Right Now

3 Dividend Growth Stocks You Can Buy and Hold Forever
JNJ

Motley Fool

a month ago

3 Dividend Growth Stocks You Can Buy and Hold Forever

Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas
JNJ

Benzinga

a month ago

Johnson & Johnson's Blockbuster Drug Tremfya Clears Plaque Psoriasis With Lesions Covering Body's Smaller Areas

JNJ

MT Newswires

a month ago

Johnson & Johnson Says Tremfya Achieves Statistical Significance Across Primary Endpoints in Phase 3b Study

New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis
JNJ

PR Newswire

a month ago

New SPECTREM study findings reveal TREMFYA® (guselkumab) effectively clears overlooked and undertreated plaque psoriasis

Is Kenvue Stock a Buy Now?
JNJ

Motley Fool

a month ago

Is Kenvue Stock a Buy Now?

Johnson & Johnson (JNJ): Legal Challenges Over Talc Products Impact Dow Performance
JNJ

Insider Monkey

a month ago

Johnson & Johnson (JNJ): Legal Challenges Over Talc Products Impact Dow Performance

Johnson & Johnson Investing $2B to Build Pharma Factory in North Carolina
JNJ

Design & Development Today

a month ago

Johnson & Johnson Investing $2B to Build Pharma Factory in North Carolina

If You Invested $10,000 In Johnson & Johnson Stock 10 Years Ago, How Much Would You Have Now?
JNJ

Benzinga

a month ago

If You Invested $10,000 In Johnson & Johnson Stock 10 Years Ago, How Much Would You Have Now?

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress
JNJ

PR Newswire

a month ago

Johnson & Johnson highlights innovative neuropsychiatry portfolio and pipeline at Psych Congress

Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government
JNJ

Motley Fool

a month ago

Meet the Only 2 Game-Changing Businesses With a Higher Credit Rating Than the U.S. Government

J&J’s Asish Xavier on biotech’s rebound in a volatile era
JNJ

BioPharma Dive

a month ago

J&J’s Asish Xavier on biotech’s rebound in a volatile era

Decoding Johnson & Johnson (JNJ): A Strategic SWOT Insight
JNJ

GuruFocus.com

a month ago

Decoding Johnson & Johnson (JNJ): A Strategic SWOT Insight

J&J’s Darzalex combination gains expanded label for multiple myeloma in Europe
JNJ

Pharmaceutical Technology

a month ago

J&J’s Darzalex combination gains expanded label for multiple myeloma in Europe

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know
JNJ

Zacks

a month ago

Investors Heavily Search Johnson & Johnson (JNJ): Here is What You Need to Know

JNJ

MT Newswires

a month ago

Johnson & Johnson's Janssen-Cilag Says EU Approves Indication Extension for Multiple Myeloma Treatment

This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock
JNJ

Motley Fool

a month ago

This Setback for Johnson & Johnson Is 1 More Green Light for Eli Lilly's Stock

5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates
JNJ

Zacks

a month ago

5 Large Drug Stocks Likely to Outpace Q3 Earnings Estimates

Johnson & Johnson's (NYSE:JNJ) investors will be pleased with their favorable 45% return over the last five years
JNJ

Simply Wall St.

a month ago

Johnson & Johnson's (NYSE:JNJ) investors will be pleased with their favorable 45% return over the last five years

JNJ

MT Newswires

a month ago

Daiwa Securities Adjusts Price Target on Johnson & Johnson to $170 From $150, Maintains Neutral Rating

The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi
JNJ

Zacks

a month ago

The Zacks Analyst Blog Highlights Johnson & Johnson, Pfizer, Roche, AbbVie and Sanofi

Boston Scientific, Edwards and Dexcom usher in second week of earnings
JNJ

MedTech Dive

a month ago

Boston Scientific, Edwards and Dexcom usher in second week of earnings

Share on Social Networks: